Kembi Therapeutics Reports Positive Interim Data from Lead Clinical Program
24 April 2026
Kembi Therapeutics has reported positive interim results from the 4CAST clinical trial, the first trial designed to test whether blocking cancer cell plasticity can prevent chemotherapy resistance in patients with metastatic triple-negative breast cancer (mTNBC).
Results were presented by Kembi's Founder and CEO, A/Prof Christine Chaffer, at the recent 2026 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
Triple-negative breast cancer is one of the most aggressive forms of breast cancer, with limited treatment options and a high rate of chemotherapy resistance. The 4CAST trial is testing seviteronel, Kembi's lead therapy, in combination with standard chemotherapy in patients whose cancer has spread and who have already received prior treatment.
What the results showed
Of the six patients evaluated and reported in the expansion phase of the trial, four responded to treatment, an objective response rate of 67%. Importantly, this included patients whose cancer had previously stopped responding to chemotherapy, suggesting that seviteronel may be helping to restore chemotherapy sensitivity.
The combination was well tolerated, with most side effects mild and related to the chemotherapy rather than seviteronel itself. The trial is also piloting a decentralised participation model, allowing patients to enrol and participate remotely. Early indications suggest this is feasible for both patients and investigators.
What this means
These early results support Kembi's core scientific hypothesis: that blocking androgen receptor signalling can prevent cancer cells from switching into a chemotherapy-resistant state, keeping treatment effective for longer.
The trial is ongoing at the Kinghorn Cancer Centre, a joint facility of St Vincent's Hospital, Sydney and the Garvan Institute of Medical Research. We look forward to sharing further updates.
This announcement contains forward-looking statements based on interim data from an early-phase clinical trial. Results are based on a small number of patients and may not be representative of outcomes in a larger population. These findings are preliminary and should not be interpreted as evidence of established efficacy. Further clinical investigation is ongoing. This announcement is for informational purposes only and does not constitute medical advice or an offer to invest in Kembi Therapeutics.
For further information, Contact Us.